Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation
Recruiting · Phase 1, Phase 2 · NCT04005469
Conditions: Ischemia Reperfusion Injury, Delayed Graft Function
At a glance
- Research payments reported, 2025
- $30,196
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 20
About the trial
- Sponsor
- Rhode Island Hospital (with University of Rhode Island, United Therapeutics)
- Tested
- Treprostinil (drug)
- Dates
- Started 2020-11-13; completion 2028-06-30
- Results posted
- Not yet
The objectives of this study are to test the preliminary safety and efficacy of a two-day peri-operative course of treprostinil in reducing ischemia-reperfusion injury in adult patients receiving a deceased donor kidney transplantation. Treprostinil, a prostacyclin analog, is expected to facilitate the restoration of blood supply to the revascularized kidney graft via its vasodilatory actions, well characterized protective effects, and longer elimination half-life. These properties and actions of treprostinil make it a strong drug candidate to reduce kidney graft dysfunction during kidney transplantation. An anticipated 20 participants undergoing deceased donor kidney transplant will be h…
From ClinicalTrials.gov, last updated 2026-04-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
United Therapeutics Corporation reported $30,196 in research payments for this study in 2025 (5 payments).
Products named: Remodulin
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.